The latest BCU (volume 5, #4) has a number of unusual features in some of the audio interviews of clinical trial investigators at this web site:
http://www.breastcancerupdate.com/20...rs/default.asp
In addition to the usual expert comments there are a number of patient interviews about their treatment.
In the case of Dr Charles Fogel these interesting tracks (if you donot want to listen to the whole interview):
(
http://www.breastcancerupdate.com/bcu2006/4/vogel.asp)
Track 2 Case discussion 1: A 61-year-old woman with metastatic breast cancer to the liver treated with
high-dose estrogen therapy
Track 14 Case discussion 5: A woman treated with trastuzumab for metastatic breast cancer since 1998
Track 21 Case discussion 6: Woman with prolonged response to trastuzumab
Track 22Patient interview: Personal perspective on living with metastatic breast cancer
Track 23Breast cancer as a chronic disease
In the case of Dr Cathy Miller most of her interview is devoted to Bevacizumab(Avastin) which is a humanized monoclonal antibody, and was the first commercially available angiogenesis inhibitor
(originally approved for colon cancer in 2004) & now tried for breast cancer.
http://www.breastcancerupdate.com/bcu2006/4/miller.asp
Two tracks (not on Avastin) of potential interest to triple negative patients & a third for low dose chemo cases:
Track 10 Potential role of small molecule tyrosine kinase inhibitors (SMTKIs) in breast cancer
Track 11Case discussion: Woman with ER/PR/HER2-negative metastatic disease treated with a SMTKI
Track 27Pilot study of adjuvant bevacizumab monotherapy versus bevacizumab with metronomic chemotherapy
The interview of Dr Jones is entirely devoted to chemo trials:
http://www.breastcancerupdate.com/bcu2006/4/jones.asp